IL-33–activated ILC2s not only coordinate with cytotoxic T cells to limit tumor growth (175), but also promote the formation of tertiary lymphoid structures (TLS) through lymphotoxin (LTα and LTβ) expression. The gene discussed is IL33; the disease is neoplasm.